Helperby Announcements

Are New Antibiotic Combinations The Solution To The AMR Crisis?

Combinations of old antimicrobials such as Helperby’s colistin and azidothymidine are a possible alternative to developing new chemical entities, because they cost one tenth of the price. A Global
19 Oct 2019

The New England Journal of Medicine

The New England Journal of Medicine announces that Azidothymidine produces synergistic activity in combination with Colistin against antibiotic-resistant Enterobacteriaceae. Antimicrobial Agents Chemother. doi:10.1128/AAC.01630-18. The NEJM review entitled Colistin-Azidothymidine
24 Sep 2019

Antibiotic Resistance Plan To Fight Urgent Global Threat

The World Health Organization recognises antimicrobial resistance (AMR) as one of the most pressing global threats to medicine. Without effective antibiotics, much of the success of modern medicine, such as
19 Feb 2019

Helperby to collaborate with UCLA on new fast track antibiotic therapies

Helperby has announced a collaboration with Dr. Pamela Yeh and her team at the Department of Ecology and Evolutionary Biology, University of California, Los Angeles (UCLA). Dr Yeh recently published
12 Nov 2018

Helperby Therapeutics announces study results active against the WHO Critical Priority Carbapenem resistant bacterial pathogens

Helperby Therapeutics announces study results demonstrating promise of its unique combination antibiotic therapy - active against the WHO Critical Priority Carbapenem resistant bacterial pathogens The combination of azidothymidine (AZT) and
15 Jun 2018

ECCMID Published Papers - Safety & Pharmacokinetics of i.v azidothymidine alone & combined with Colistin

P2195 Safety and pharmacokinetics of i.v. azidothymidine alone and combined with colistin being developed for the treatment of carbapenem - and colistin- resistant Enterobacteriaceae (phase-1-study) Azidothymidine (AZT) in
26 Apr 2018

ECCMID 2018 Published Papers- Azidothymidine

O0574 Azidothymidine is bactericidal against carbapenem-resistant Enterobacteriaceae and produces synergistic activity in combination with colistin against multidrug-resistant Enterobacteriaceae Bacterial infections remain the leading killer worldwide which is worsened by the
25 Apr 2018

Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy - effective against the WHO Critical Priority Carbapenem resistant bacteria

The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. In addition, AZT and
25 Apr 2018

Rise of Superbugs Puts Everyday Surgical Operations In Jeopardy

Tens of thousands of patients in Britain are struck down by superbugs because antibiotics to protect them during surgery have failed, a global study says. One in five infections picked
14 Feb 2018

Latest European Data Shows Increasing Antibiotic Resistance

The European Centre for Disease Prevention and Control (ECDC) released the latest annual data on antimicrobial resistance trends in 30 European Union (EU) and European Economic Area (EEA) countries today, in
17 Nov 2017

New Treatments To Solve Antibiotic Crisis Have Potential To Reach The Market As Early As 2020

Doctors increasingly rely on last resort antibiotics such as carbapenems and colistin, but as harmful bacteria continue to mutate, this final line of resistance will eventually fail. The World Health
13 Nov 2017

Breaking Resistance One Antibiotic At A Time

Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.
26 May 2016

Helperby Therapeutics held a pre-IND meeting with the FDA

On March 9th 2016 Helperby Therapeutics held a pre-IND meeting with the FDA division of Anti-Infective products. The outcome is a road map for the clinical development of a drug product
09 Apr 2016